Drug Type Small molecule drug |
Synonyms MR837 |
Target |
Mechanism NSD2 inhibitors(nuclear receptor binding SET domain protein 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC16H14N2OS |
InChIKeyWYAGGMZTARRIDX-UHFFFAOYSA-N |
CAS Registry1210906-48-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Preclinical | CA | 11 Feb 2021 | |
Multiple Myeloma | Preclinical | CA | 11 Feb 2021 |